3098
ERYFOTONA AK-NMSC FLUID 50 ML
ERYFOTONA AK-NMSC FLUID 50 ML
Secure payment
Discreet and sanitized package
Fast and safe shipping
Description
Description
ISDIN
Eryfotona
AK-NMSC
Description Prevention and protective adjuvant treatment of actinic keratosis (AK) and other forms of non-melanoma skin cancer (NMSC). Reduces and improves the associated subclinical skin cancer. Shake before use.
How to use
Apply generously to the entire affected area and to areas at risk from chronic sun exposure (face, forehead, ears, cheeks, scalp and back of the hands) twice a day, in the morning and early afternoon - photolyase is activated by light.
Components
Repairsomes (UVB-UVA Filter complex + plankton extract), bisabolol, tocopheryl acetate, panthenol, excipients qs.
Warnings
For external use only.
Conservation
Store between 8°C and 25°C.
Shelf life in intact packaging: 36 months.
Shelf life after opening: 6 months.
Format
50 ml pack.
Cod. 690026270
3098
ERYFOTONA AK-NMSC FLUID 50 ML
ERYFOTONA AK-NMSC FLUID 50 ML
Couldn't load pickup availability
Product images are purely indicative and may not be fully representative of the packaging and product features, as they may vary in color, size, or content. Any decorations, gift wrapping, and items included in the images for product presentation purposes will not be shipped with orders. Product names, ingredients, and percentages indicated in the descriptions are purely indicative and may be subject to change or updates by the manufacturers. Due to the impossibility of updating these updates in real time, the photos and technical information of the products listed on farmaInnovation.it may differ from those shown on the label or otherwise disclosed by the manufacturers. The only identifying element is the MINSAN (Ministry of Health) code. Farmacia Barni, farmainnovation.it , does not guarantee the accuracy and timeliness of the information published and declines all responsibility for any errors, omissions, or failure to update it. farmainnovation.it assumes no responsibility for damages of any kind that may arise from accessing the published information.
